Literature DB >> 8980771

MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

Agar dilution MIC methodology was used to test the activities of GV 118819X (sanfetrinem), ampicillin, amoxicillin, amoxicillin-clavulanate, cefpodoxime, loracarbef, levofloxacin, clarithromycin, ceftriaxone, imipenem, and vancomycin against 53 penicillin-susceptible, 84 penicillin-intermediate and 74 penicillin-resistant pneumococci isolated in the United States. GV 118819X was the most active oral beta-lactam, with MIC at which 50% of the isolates were inhibited (MIC50)/MIC90 values of 0.008/0.03, 0.06/0.5, and 0.5/1.0 micrograms/ml against penicillin-susceptible, -intermediate, and -resistant stains, respectively. Amoxicillin and amoxicillin in the presence of clavulanate (2:1) were the second most-active oral beta-lactams, followed by ampicillin and cefpodoxime; loracarbef was not active against penicillin-intermediate and -resistant strains. Clarithromycin was most active against penicillin-susceptible strains but was less active against intermediate and resistant stains. All pneumococcal stains were inhibited by ceftriaxone and imipenem at MICs of < or = 4.0 and < or = 1.0 micrograms/ml, respectively. The activities of levofloxacin and vancomycin were unaffected by penicillin susceptibility. Time-kill studies of three penicillin-susceptible, three penicillin-intermediate, and three penicillin-resistant pneumococci showed that all compounds, at the broth microdilution MIC, yielded 99.9% killing of all strains after 24 h. Kinetic patterns of all oral beta-lactams, ceftriaxone, and vancomycin were similar relative to the MIC, with 90% killing of all strains first observed after 12 h. However, killing by amoxicillin-clavulanate, imipenem, and levofloxacin was slightly faster and that by clarithromycin was slower than that by the above-described drugs. At 2 x the MIC, more strains were killed earlier than was the case at the MIC, but the pattern seen at the MIC prevailed. When MICs and kill kinetics were combined, sanfetrinem was the most active oral antipneumococcal agent in this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980771      PMCID: PMC163676     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

Review 2.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

7.  Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.

Authors:  D J Tweardy; M R Jacobs; W T Speck
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

8.  Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

Authors:  S K Spangler; M R Jacobs; G A Pankuch; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

9.  Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.

Authors:  C T Nelson; E O Mason; S L Kaplan
Journal:  Pediatr Infect Dis J       Date:  1994-07       Impact factor: 2.129

Review 10.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

View more
  9 in total

1.  Electrostatic and structural similarity of classical and non-classical lactam compounds.

Authors:  M Coll; J Frau; B Vilanova; J Donoso; F Muñoz
Journal:  J Comput Aided Mol Des       Date:  2001-09       Impact factor: 3.686

2.  In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.

Authors:  M Hikida; K Itahashi; A Igarashi; T Shiba; M Kitamura
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

Authors:  S Miyazaki; T Hosoyama; N Furuya; Y Ishii; T Matsumoto; A Ohno; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.

Authors:  E Di Modugno; R Broggio; I Erbetti; J Lowther
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae.

Authors:  F Sifaoui; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.

Authors:  Y Q Liu; Y Z Zhang; P J Gao
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.

Authors:  S Tamura; S Miyazaki; K Tateda; A Ohno; Y Ishii; T Matsumoto; N Furuya; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.